Acquired disorders of platelet function

Platelets in Hematologic and Cardiovascular Disorders: A Clinical Handbook

Volumn , Issue , 2007, Pages 225-241

  Kroll, Michael H ^a   Hassan, Amy A ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78651394293     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511545276.015     Document Type: Chapter

References (101)

1. Hassan AA, Kroll MH. Acquired disorders of platelet function. (Educational Program of the American Society of Hematology). Hematology 2005;403-8.
2. Coller BS, Schneiderman PI. Clinical evaluation of hemorrhagic disorders: the bleeding history and differential diagnosis of purpura. In: Hoffman, Benz, Shattil, Furie, Cohen, Silberstein, McGlave (eds). Hematology. Basic Principles and Practice, 4th ed. Philadelphia: Elsevier, 2005:1975-2000.
3. Sadler JE, Rodeghiero F. Provisional criteria for the diagnosis of VWD type 1. J Thromb Haemost 2005;3: 775-7.
4. Nitu-Whalley IC, Lee CA, Griffioen A, Jenkins PV, Pasi KJ. Type 1 vonWillebrand disease - a clinical retrospective study of the diagnosis, the influence of the ABO blood group and the role of the bleeding history. Br J Haematol 2000;108:259-64.
5. Hayward CPM, Harrison P, Cattaneo M, Ortel TL, Rao AK (for the Platelet Physiology Subcommittee of the SSC/ISTH). Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006;4:312-19.
6. Harrison P. The role of PFA-100 testing in the investigation and management of haemostatic defects in children and adults. Br J Haematol 2005;130:3-10.
7. Quiroga T, Goycoolea M, Muñoz B, et al. Template bleeding time and PFA-100 have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: comparative study in 148 patients. J Thromb Haemost 2004;2: 892-8.
8. Malpass TW, Savage B, Hanson SR, Slichter SJ, Harker LA. Correlation between prolonged bleeding time and depletion of platelet dense granule ADP in patients with myelodysplastic and myeloproliferative disorders. J Lab ClinMed 1984;103:894-904.
9. Posan E, McBane RD, Grill DE, Motsko CL, Nichols WL. Comparison of PFA-100 testing and bleeding time for detecting platelet hypofunction and vonWillebrand disease in clinical practice. Thromb Haemost 2003;90:483-90.
10. Michelson AD. Platelet function testing in cardiovascular diseases. Circulation 2004;110:e489-93.
11. Nickels RM, Seyfert UT, Wenzel E, Menger MD, Vollmar B. A simple and reproducible method to reliably assess platelet activation. Thromb Res 2003;110:53-6.
12. Fricke W, Kouides P, Kessler C, et al. A multicenter clinical evaluation of the Clot Signature Analyzer. J Thromb Haemost 2004;2:763-8.
13. Michelson AD, Frelinger AL, Furman MI. Current options in platelet function testing. AmJ Cardiol 2006;98(Suppl): S4-10.
14. Koscielny J, Aslan T, Meyer O, et al. Use of the platelet reactivity index by Grotemeyer, platelet function analyzer, and retention test Homburg to monitor therapy with antiplatelet drugs. Semin Thromb Hemost 2005;31:464-9.
15. George JN, Shattil SJ. The clinical importance of acquired abnormalities of platelet function.NEngl J Med 1991;324:27-39.
16. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. The Seventh ACCP Conference on Antithrombotic and Thrombolytic therapy. Chest 2004;126:234S-64S.
17. Amrein PC, Ellman L, Harris WH. Aspirin-induced prolongation of bleeding time and perioperative blood loss. JAMA 1981;245:1825-8.
18. Wilhite DB, Comerota AJ, Schmieder FA, Throm RC, Gaughan JP, Rao AK.Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. J Vasc Surg 2003;38:710-13.
19. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. NEngl J Med 2005;353:2373-83.
20. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.NEngl J Med 2001;345:1809-17.
21. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost 2003;1:1710-13.
22. Sanderson S, Emery J, Baglin T, Kinmonth AL. Narrative review: aspirin resistance and its clinical implications. Ann InternMed 2005;142:370-80.
23. Michelson AD, Cattaneo M, Eikelboom JW, et al. on behalf of the platelet physiology subcommittee of the SSC of the ISTH. Aspirin resistance: position paper of theWorking Group on Aspirin Resistance. J Thromb Haemost 2005;3:1309-11.
24. Chen W-H, Lee P-Y, Ng W, Tse H-F, Lau C-P. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J AmColl Cardiol 2004;43:1122-6.
25. Goldenberg NA, Jacobson L, Manco-Johnson MJ. Brief communication: duration of platelet dysfunction after a 7 day course of ibuprofen. Ann InternMed 2005;142: 506-9.
26. Capone ML, Sciulli MG, Tacconelli S, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J AmColl Cardiol 2005;45:1295-1301.
27. Savi P, Herbert JM. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost 2005;31:174-83.
28. Schleinitz MD, Heidenreich PA. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. Ann InternMed 2005;142:251-9.
29. Bhatt DL, Fox KAA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-17.
30. Harder S, Klinkhardt U, Alvarez JM. Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelet therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet 2004;43:963-81.
31. White MM, Krishnan R, Kueter TJ, Jacoski MV, Jennings LK. The use of the point of care Helena ICHOR/Plateletworks and the Accumetrics Ultegra RPFA for assessment of platelet function with GPIIb-IIIa antagonists. J Thromb Thrombolysis 2004;18:163-9.
32. Steinhubl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001;103:2572-8.
33. Kessler CM. Antidotes to haemorrhage: recombinant activated factor VIIa. Best Pract Res Clin Haematol 2004;17:183-97.
34. Hamm CW. Anti-integrin therapy. Annu RevMed 2003;54:425-35.
35. Quinn MJ, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword? Circulation 2002;106:379-85.
36. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.
37. FitzGerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004;351:1709-11.
38. Bennett JS, Daugherty A, Herrington D, Greenland P, Roberts H, Taubert KA. The use of nonsteroidal anti-inflammatory drugs (NSAIDs): a science advisory from the American Heart Association. Circulation 2005;111:1713-16.
39. McCulley TJ, Luu JK, Marmor MF, Feuer WJ. Effects of sildenafil citrate (Viagra) on choroidal congestion. Opthalmologica 2002;216:455-8.
40. Li Z, Xi X, Gu M, et al. A stimulatory role for cGMP-dependent protein kinase in platelet activation. Cell 2003;112:77-86.
41. Feil R, Lohmann SM, de Jonge H, Walter U, Hofmann F. Cyclic GMP-dependent protein kinases and the cardiovascular system. Insights from genetically modified mice. Circ Res 2003;93:907-16.
42. Hofmann F. The biology of cyclic GMP-dependent protein kinases. J Biol Chem 2005;280:1-4.
43. Shattil SJ, Bennett JS, McDonough M, Turnbull J. Carbenicillin and penicillin G inhibit platelet function in vitro by impairing the interaction of agonists with the platelet surface. J Clin Invest 1980;65:329-37.
44. Notarbartolo A, Davi G, Averna M, et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995;15:247-51.
45. Laine-Cessac P, Shoaay I, Garre JB, Glaud V, Turcant A, Allain P. Study of haemostasis in depressive patients treated with fluoxetine. Pharmacoepidemiol Drug Safety 1998;7:S54-7.
46. Zwerina J, Landsteiner H, Leitgeb U, et al. The influence of VIP and epoprostenol on platelet CD62P expression and primary haemostasis in vitro. Platelets 2004;15: 55-60.
47. AbebeW. Herbal medication: potential for adverse interactions with analgesic drugs. J Clin Pharm Ther 2002;27:391-401.
48. Middleton E Jr, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implication for inflammation, heart disease, and cancer. Pharmacol Rev 2000;52:673-751.
49. Janossy K, Ball DR, Jefferson P. Platelet function and diet. Anaesthesia 2006;61:508-9.
50. Paparella D, Brister SJ, Buchanan MR. Coagulation disorders of cardiopulmonary bypass: a review. Intens Care Med 2004;30:1873-81.
51. Mangano DT, Tudor IC, Dietzel C, et al. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006;354: 353-65.
52. Mangano DT, Tudor IC, Dietzel C, et al. FDA statement regarding new trasylol data. September 29 2006. http://www.fda.gov/bbs/topics/NEWS/2006/NEW01472.html
53. Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost 2004;30: 579-89.
54. Noris M, Remuzzi G. Uremic bleeding: closing the circle after 30 years of controversies? Blood 1999;94:2569-74.
55. Bonomini M, Dottori S, Amoroso L, Arduini A, Sirolli V. Increased platelet phosphatidylserine exposure and caspase activation in chronic uremia. J Thromb Haemost 2004;2:1275-81.
56. Zwaginga JJ. Hemodialysis, erythropoietin and megakaryocytopoiesis: factors in uremic thrombocytopathy and thrombophilia. J Thromb Haemost 2004;2:1272-4.
57. Remuzzi G, Ingelfinger JR. Correction of anemia: payoffs and problems. N Engl J Med 2006;355:2144-6.
58. Escolar G, Cases A, Vinas M, et al. Evaluation of acquired platelet dysfunction in uremic and cirrhotic patients using the platelet function analyzer (PFA-100): influence of hematocrit elevation. Haematologica 1999;84:614-9.
59. Zupan IP, Sabovic M, Salobir B, Ponikvar JB, Cernelc P. Utility of in vitro closure time test for evaluating platelet-related primary hemostasis in dialysis patients. Am J Kidney Dis 2003;42:746-51.
60. Moal V, Brunet P, Dou L, Morange S, Sampol J, Berland Y. Impaired expression of glycoproteins on resting and stimulated platelets in uraemic patients. Nephrol Dial Transplant 2003;18:1834-41.
61. Mannucci PM. Hemostatic drugs. N Engl J Med 1998;339:245-53.
62. Van Thiel DH, George M, Mindikoglu AL, Baluch MH, Dhillon S. Coagulation and fibrinolysis in individuals with advanced liver disease. Turk J Gastroenterol 2004;15:67-72.
63. Lisman T, Bongers TN, Adelmeijer J, et al. Elevated levels of vonWillebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006;44:53-61.
64. Sieghart W, Homoncik M, Jilma B, et al. Antiviral therapy decreases GpIIb/IIIa activation of platelets in patients with chronic hepatitis C. Thromb Haemost 2006;95:260-6.
65. Bosch J, Thabut D, Bendtsen F, et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology 2004;127:1123-30.
66. Pareti FI, Capitanio A, Mannucci PM. Acquired storage pool disease in platelets during disseminated intravascular coagulation. Blood 1976;48:511-15.
67. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004;350:114-24.
68. Elliot MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005;128:275-90.
69. Michiels JJ, Budde U, van der Planken M, van Vliet HH, Schroyens W, Berneman Z. Acquired vonWillebrand syndromes: clinical features, aetiology, pathophysiology, classification and management. Best Pract Res Clin Haematol 2001;14:401-36.
70. Gunz FW. Hemorrhagic thrombocythemia: a critical review. Blood 1960;15:706-23.
71. Budde U, Scharf RE, Franke P, Hartmann-Budde K, Dent J, Ruggeri ZM. Elevated platelet count as a cause of abnormal vonWillebrand factor multimer distribution in plasma. Blood 1993;82:1749-57.
72. Schafer AI. Bleeding and thrombosis in the myeloproliferative disorders. Blood 1984;64:1-12.
73. Barbui T, Finazzi G.Myeloproliferative disease in pregnancy and other management issues. Hemotology 2006;1:246-52.
74. Ganguly P, Sutherland SB, Bradford HR. Defective binding of thrombin to platelets in myeloid leukaemia. Br J Haematol 1978;39:599-605.
75. Sultan Y, Caen JP. Platelet dysfunction in preleukemic states and in various types of leukemia. Ann N Y Acad Sci 1972;201:300-6.
76. Rosove MH, Naeim F, Harwig S, Zighelboim J. Severe platelet dysfunction in hairy cell leukemia with improvement after splenectomy. Blood 1980;55:903-6.
77. Pogliani EM, Colombi M, Cofrancesco E, Salvatore M, Fowst C. Platelet dysfunction in acute megakaryoblastic leukemia. Acta Haematol 1989;81:1-4.
78. Hendrick AM, Shah S, Raich PC. Platelet dysfunction in acute megakaryoblastic leukemia. Arch Pathol LabMed 1984;108:63-4.
79. Gerrard JM, Stoddard SF, Shapiro RS, et al. Platelet storage pool deficiency and prostaglandin synthesis in chronic granulocytic leukaemia. Br J Haematol 1978;40: 597-607.
80. Okuma M, Takayama H, Uchino H. Subnormal platelet response to thromboxane A2 in a patient with chronic myeloid leukaemia. Br J Haematol 1982;51:469-77.
81. Smith RE, Saab GA. Platelet dysfunction in acute lymphatic leukemia. Arch InternMed 1981;141:269-70.
82. Cortelazzo S, Viero P, D'Emilio A, de Gaetano G, Barbui T. Platelet dysfunction in splenectomized patients with hairy cell leukemia. Eur J Cancer Clin Oncol 1986;22: 935-7.
83. Eby C, Blinder M. Hemostatic complications associated with paraproteinemias. Curr Hematol Rep 2003;2:388-94.
84. Perkins HA, MacKenzie MR, Fudenberg HH. Hemostatic defects in dysproteinemias. Blood 1970;35:695-707.
85. Pachter MR, Johnson SA, Basinski DH. The effect of macroglobulins and their dissociation units on release of platelet factor 3. Thromb Diath Haemorrh 1959;3:501-9.
86. McGrath KM, Stuart JJ, Richards F II. Correlation between serum IgG, platelet membrane IgG, and platelet function in hypergammaglobulinaemic states. Br J Haematol 1979;42:585-91.
87. DiMinno G, Coraggio F, Cerbone AM, et al. A myeloma paraprotein with specificity for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder. J Clin Invest 1986;77:157-64.
88. Federici AB, Stabile F, Castaman G, Canciani MT, Mannucci PM. Treatment of acquired vonWillebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. Blood 1998;92:2707-11.
89. Vincentelli A, Susen S, Le Tourneau T, et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 2003;349:343-9.
90. Deckmyn H, Vanhoorelbeke K, Peerlinck K. Inhibitory and activating human antiplatelet antibodies. Bailliere's Clin Haematol 1998;11:343-59.
91. Malik U, Dutcher JP, Oleksowicz L. Acquired Glanzmann's thrombasthenia associated with Hodgkin's lymphoma: a case report and review of the literature. Cancer 1998;82:1764-8.
92. Tholouli E, Hay CR, O'Gorman P, Makris M. Acquired Glanzmann's thrombasthenia without thrombocytopenia: a severe acquired autoimmune bleeding disorder. Br J Haematol 2004;127:209-13.
93. Thomas RV, Bessos H, Turner ML, Horn EH, Ludlam CA. The successful use of plasma exchange and immunosuppression in the management of acquired Glanzmann's thrombasthenia. Br J Haematol 2002;119:878-80.
94. Ferraris VA, Ferraris SP, Joseph O, Wehner P, Mentzer RM, Jr. Aspirin and postoperative bleeding after coronary artery bypass grafting. Ann Surg 2002;235:820-7.
95. Ascione R, Ghosh A, Rogers CA, Cohen A, Monk C, Angelini GD. In-hospital patients exposed to clopidogrel before coronary artery bypass graft surgery: a word of caution. Ann Thorac Surg 2005;79:1210-16.
96. Chen L, Bracey AW, Radovancevic R, et al. Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting. J Thorac Cardiovasc Surg 2004;128: 425-31.
97. Avidan MS, Alcock EL, Da Fonseca J, et al. Comparison of structured use of routine laboratory tests or near-patient assessment with clinical judgement in the management of bleeding after cardiac surgery. Br J Anaesth 2004;92: 178-86.
98. Poston R, Gu J, Manchio J, et al. Platelet function tests predict bleeding and thrombotic events after off-pump coronary bypass grafting. Eur J Cardiothorac Surg 2005;27:584-91.
99. Hertfelder H-J, Bös M, Weber D, Winkler K, Hanfland P, Preusse CJ. Perioperative monitoring of primary and secondary hemostasis in coronary artery bypass grafting. Semin Thromb Hemost 2005;31:426-40.
100. Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). J Am Coll Cardiol 2004;44:e213-310.
101. Bracey AW, Grigore AM, Nussmeier NA. Impact of platelet testing on presurgical screening and implications for cardiac and noncardiac surgical procedures. AmJ Cardiol 2006;98:S25-32.